Warfarin ( DrugBank: Warfarin )

---

13 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
8	Huntington disease	1
13	Multiple sclerosis/Neuromyelitis optica	1
19	Lysosomal storage disease	1
46	Malignant rheumatoid arthritis	3
49	Systemic lupus erythematosus	3
66	IgA nephropathy	3
85	Idiopathic interstitial pneumonia	1
86	Pulmonary arterial hypertension	1
88	Chronic thromboembolic pulmonary hypertension	3
91	Budd-Chiari syndrome	1
96	Crohn disease	1
97	Ulcerative colitis	1

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02305030 (ClinicalTrials.gov)	March 2014	28/11/2014	Effect of Opicapone at Steady State on Warfarin Pharmacokinetics	Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers	Parkinson's Disease	Drug: BIA 9-1067;Drug: Warfarin	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	Both	20	Phase 1	NULL
2	NCT02169440 (ClinicalTrials.gov)	June 2009	24/1/2012	Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin	Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers	Parkinson's Disease (PD)	Drug: BIA 9-1067;Drug: Warfarin	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	20	Phase 1	Portugal

8. Huntington disease

---

Clinical trials : 229 /  Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00827034 (ClinicalTrials.gov)	February 2009	20/1/2009	A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects	A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects	Alzheimer's Disease;Huntington's Disease	Drug: Warfarin;Drug: Dimebon	Pfizer	Medivation, Inc.	Completed	18 Years	55 Years	All	14	Phase 1	United States

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01462318 (ClinicalTrials.gov)	November 2011	14/7/2011	An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis	A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab)	Biogen	NULL	Completed	18 Years	65 Years	All	133	Phase 3	United States;Czech Republic;Hungary;Poland;Russian Federation

19. Lysosomal storage disease

---

Clinical trials : 854 /  Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00683189 (ClinicalTrials.gov)	June 2007	21/5/2008	Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy	Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy	Metachromatic Leukodystrophy	Drug: Warfarin	The Cooper Health System	NULL	Completed	1 Year	10 Years	Both	10	N/A	United States

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04246762 (ClinicalTrials.gov)	April 6, 2021	27/1/2020	Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4	A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4	Rheumatoid Arthritis	Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin+ Vitamin K;Drug: Midazolam	R-Pharm International, LLC	IQVIA RDS Ireland Ltd;Thermo Fisher Scientific	Recruiting	18 Years	70 Years	All	15	Phase 1	Bulgaria;Moldova, Republic of
2	NCT01636557 (ClinicalTrials.gov)	October 11, 2012	6/7/2012	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis	A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine	Janssen Research & Development, LLC	NULL	Completed	18 Years	65 Years	All	12	Phase 1	Germany;Korea, Republic of;Moldova, Republic of;South Africa
3	NCT01311622 (ClinicalTrials.gov)	March 2011	21/2/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects	An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects	Rheumatoid Arthritis;Healthy Subjects	Drug: warfarin;Drug: fostamatinib	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	15	Phase 1	United Kingdom

49. Systemic lupus erythematosus

---

Clinical trials : 946 /  Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03684564 (ClinicalTrials.gov)	September 2020	13/8/2018	RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome	Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open Label, Phase II/III, Non-inferiority Trial	Antiphospholipid Syndrome;Systemic Lupus Erythematosus;Stroke;Ischemic Stroke;Brain Ischemia	Drug: Rivaroxaban;Drug: Warfarin	University College, London	Arthritis Research UK;King's College London;University College London Hospitals;Hammersmith Hospitals NHS Trust;Guy's and St Thomas' NHS Foundation Trust;Barts & The London NHS Trust;King's College Hospital NHS Trust;Manchester University NHS Foundation Trust;Barking, Havering and Redbridge University Hospitals NHS Trust;St George's University Hospitals NHS Foundation Trust	Not yet recruiting	18 Years	N/A	All	140	Phase 2/Phase 3	NULL
2	EUCTR2018-001735-49-GB (EUCTR)	01/07/2019	22/01/2019	RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome	Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial - RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome	Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: Rivaroxaban Product Name: Rivaroxaban INN or Proposed INN: Rivaroxaban Other descriptive name: Trade Name Xarelto Trade Name: Warfarin Sodium Product Name: Warfarin Sodium INN or Proposed INN: Warfarin sodium	University College London	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 2;Phase 3	United Kingdom
3	EUCTR2012-002345-38-GB (EUCTR)	30/10/2012	08/10/2012	Comparison of rivaroxaban (Xarelto®; Bayer HealthCare), fixed-dose oral anticoagulant (blood thinner), versus warfarin in patients with antiphospholipid syndrome (called APS), with or without 'lupus' (systemic lupus erythematosus)	A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. - Rivaroxaban in Antiphospholipid Syndrome (RAPS)	Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE). MedDRA version: 14.1;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Xarelto Product Name: Rivaroxaban INN or Proposed INN: Rivaroxaban Other descriptive name: Trade name Xarelto Trade Name: The generic name is warfarin and many producers will be involved Product Name: Warfarin INN or Proposed INN: Warfarin	University College London	NULL	Not Recruiting			Female: yes Male: yes	156	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

66. IgA nephropathy

---

Clinical trials : 255 /  Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-C000000363	2001/08/01	14/05/2007	A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety		IgA nephropathy in children	prednisolone+mizoribine for 2 years prednisolone+mizoribine+warfarin+dipyridamole for 2 years	The Japanese Pediatric IgA Nephropathy ofTreatment Study Group	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	80	Not selected	Japan
2	JPRN-C000000374	1998/08/01	01/04/2006	A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.		IgA nephropathy in children	prednisolone+warfarin+dipyridamole for 2 years	The Japanese Pediatric IgA Nephropathy ofTreatment Study Group	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	20	Not selected	Japan
3	JPRN-C000000375	1998/08/01	01/04/2006	A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children.		IgA nephropathy in children	prednisolone+mizoribine+warfarin+dipyridamole for 2 years	The Japanese Pediatric IgA Nephropathy of Treatment Study Group	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	20	Not selected	Japan

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00957242 (ClinicalTrials.gov)	October 2009	10/8/2009	AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis	AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)	Idiopathic Pulmonary Fibrosis	Drug: warfarin;Drug: placebo	Duke University	National Heart, Lung, and Blood Institute (NHLBI);Duke Clinical Research Institute	Terminated	35 Years	80 Years	All	145	Phase 3	United States

86. Pulmonary arterial hypertension

---

Clinical trials : 1,181 /  Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04994119 (ClinicalTrials.gov)	February 23, 2018	29/7/2021	Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics	An Open-label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 400 mg on Warfarin Pharmacokinetics in Healthy Subjects Under Fasting Conditions	Pulmonary Arterial Hypertension	Drug: BIA 5-1058;Drug: Warfarin	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	26	Phase 1	Germany

88. Chronic thromboembolic pulmonary hypertension

---

Clinical trials : 159 /  Drugs : 118 - (DrugBank : 23) / Drug target genes : 13 - Drug target pathways : 53

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04730037 (ClinicalTrials.gov)	April 9, 2021	25/1/2021	Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)	An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hypertension Taking Warfarin (Vitamin K Antagonist) at Baseline: KABUKI	CTEPH	Drug: Edoxaban;Drug: Warfarin Potassium;Drug: Warfarin Potassium placebo;Drug: Edoxaban placebo	Kyushu University	Daiichi Sankyo Co., Ltd.	Recruiting	20 Years	85 Years	All	74	Phase 3	Japan
2	JPRN-jRCT2071200098	09/04/2021	08/02/2021	Phase III Investigator-Initiated Trial to Investigate Safety and Efficacy of Edoxaban in Patients with Chronic Thromboembolic Pulmonary Hypertension	An Investigator-initiated, multicenter, phase 3, randomized, single-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of edoxaban versus warfarin (Vitamin K antagonist) in subjects with chronic thromboembolic pulmonaty hypertension taking warfarin (Vitamin K antagonist) at baseline - KABUKI	Chronic Thromboembolic Pulmonary Hypertension CTEPH, DOAC, warfarin	Oral administeration of (1) or (2) (1) Edoxaban group - Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily over 60 kg: 60 mg once daily (reduced to 30 mg once daily depending on renal function and concomitant medications) - Warfarin K 1 mg placebo tablets once daily (2)Warfarin group - Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily over 60 kg: 60 mg once daily (reduced to 30 mg once daily depending on renal function and concomitant medications) - Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)	Abe Kohtaro	NULL	Recruiting	>= 20age old	<= 85age old	Both	74	Phase 3	Japan
3	JPRN-UMIN000018520	2016/01/01	01/01/2016	Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertension		CTEPH (chronic thromboembolic pulmonary hypertension)	Initiation of once-daily Edoxaban(60mg) during 6 months after 2 days discontinuation of warfarin	Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	60	Phase 4	Japan

91. Budd-Chiari syndrome

---

Clinical trials : 4 /  Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100046725	2022-01-01	2021-05-27	The efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty	To compare the efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty	Budd-Chiari syndrome	Warfarin group:oral take Warfarin;Rivaroxaban group:oral take rivaroxaban;	The First Affiliated Hospital of Zhengzhou University	NULL	Recruiting	18	75	Both	Warfarin group:40;Rivaroxaban group:40;	N/A	China

96. Crohn disease

---

Clinical trials : 2,400 /  Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03358706 (ClinicalTrials.gov)	February 2, 2018	27/11/2017	A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis	A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis.	Crohn Disease;Ulcerative Colitis	Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	75 Years	All	57	Phase 1	United States;Belgium;Germany;United Kingdom;Austria;Denmark;Sweden

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03358706 (ClinicalTrials.gov)	February 2, 2018	27/11/2017	A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis	A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis.	Crohn Disease;Ulcerative Colitis	Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	75 Years	All	57	Phase 1	United States;Belgium;Germany;United Kingdom;Austria;Denmark;Sweden

Back to top